 |
| (Source: Boehringer-ingelheim) |
Korean pharmaceutical companies Dongwha Pharm and Kukje Pharma have prevailed in a pair of non-infringement proceedings against Boehringer Ingelheim International GmbH, with the Korean Intellectual Property Trial and Appeal Board (IPTAB) ruling that the companies did not infringe the German drugmaker's diabetes treatment patent.
In decisions issued on March 27, 2025, the IPTAB held that the companies' products do not fall within the scope of Korean Patent No. 1611314, titled "DPP-IV Inhibitor Combined with a Further Antidiabetic Agent, Tablets Comprising Such Formulations, Their Use and Process for Their Preparation." Dongwha filed its request for adjudication in January 2024, while Kukje initiated its action in October 2023.
The patent at issue covers fixed-dose combination formulations containing a DPP-4 inhibitor and an additional antidiabetic agent, typically used to improve blood glucose control in diabetic patients. The technology enables the combination of multiple active ingredients into a single tablet to enhance patient compliance.
Boehringer Ingelheim may challenge the IPTAB decisions by filing cancellation actions with the Korean Patent Court.
Several other Korean pharmaceutical companies — including Shinil Pharmaceutical, Aju Pharm, Huons, Biochem Korea, and Korea United Pharm — have also filed similar non-infringement actions between November and December 2023 concerning the same patent.
Comments
Post a Comment